These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
584 related articles for article (PubMed ID: 26272943)
1. Amyloid fibrils are the molecular trigger of inflammation in Parkinson's disease. Gustot A; Gallea JI; Sarroukh R; Celej MS; Ruysschaert JM; Raussens V Biochem J; 2015 Nov; 471(3):323-33. PubMed ID: 26272943 [TBL] [Abstract][Full Text] [Related]
2. MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson's disease. Zhou Y; Lu M; Du RH; Qiao C; Jiang CY; Zhang KZ; Ding JH; Hu G Mol Neurodegener; 2016 Apr; 11():28. PubMed ID: 27084336 [TBL] [Abstract][Full Text] [Related]
3. Activation of innate immunity by lysozyme fibrils is critically dependent on cross-β sheet structure. Gustot A; Raussens V; Dehousse M; Dumoulin M; Bryant CE; Ruysschaert JM; Lonez C Cell Mol Life Sci; 2013 Aug; 70(16):2999-3012. PubMed ID: 23334185 [TBL] [Abstract][Full Text] [Related]
4. Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies. Codolo G; Plotegher N; Pozzobon T; Brucale M; Tessari I; Bubacco L; de Bernard M PLoS One; 2013; 8(1):e55375. PubMed ID: 23383169 [TBL] [Abstract][Full Text] [Related]
5. The nucleotide-binding domain and leucine-rich repeat protein-3 inflammasome is not activated in airway smooth muscle upon toll-like receptor-2 ligation. Hirota JA; Im H; Rahman MM; Rumzhum NN; Manetsch M; Pascoe CD; Bunge K; Alkhouri H; Oliver BG; Ammit AJ Am J Respir Cell Mol Biol; 2013 Oct; 49(4):517-24. PubMed ID: 23614732 [TBL] [Abstract][Full Text] [Related]
6. Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease. Li Y; Xia Y; Yin S; Wan F; Hu J; Kou L; Sun Y; Wu J; Zhou Q; Huang J; Xiong N; Wang T Front Immunol; 2021; 12():719807. PubMed ID: 34691027 [TBL] [Abstract][Full Text] [Related]
7. Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. Niemi K; Teirilä L; Lappalainen J; Rajamäki K; Baumann MH; Öörni K; Wolff H; Kovanen PT; Matikainen S; Eklund KK J Immunol; 2011 Jun; 186(11):6119-28. PubMed ID: 21508263 [TBL] [Abstract][Full Text] [Related]
9. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease. Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273 [TBL] [Abstract][Full Text] [Related]
10. Dl-3-n-Butylphthalide Rescues Dopaminergic Neurons in Parkinson's Disease Models by Inhibiting the NLRP3 Inflammasome and Ameliorating Mitochondrial Impairment. Que R; Zheng J; Chang Z; Zhang W; Li H; Xie Z; Huang Z; Wang HT; Xu J; Jin D; Yang W; Tan EK; Wang Q Front Immunol; 2021; 12():794770. PubMed ID: 34925379 [TBL] [Abstract][Full Text] [Related]
11. Binding of Noradrenaline to Native and Intermediate States during the Fibrillation of α-Synuclein Leads to the Formation of Stable and Structured Cytotoxic Species. Singh P; Bhat R ACS Chem Neurosci; 2019 Jun; 10(6):2741-2755. PubMed ID: 30917654 [TBL] [Abstract][Full Text] [Related]
12. Mechanistic basis for receptor-mediated pathological α-synuclein fibril cell-to-cell transmission in Parkinson's disease. Zhang S; Liu YQ; Jia C; Lim YJ; Feng G; Xu E; Long H; Kimura Y; Tao Y; Zhao C; Wang C; Liu Z; Hu JJ; Ma MR; Liu Z; Jiang L; Li D; Wang R; Dawson VL; Dawson TM; Li YM; Mao X; Liu C Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34172566 [TBL] [Abstract][Full Text] [Related]
13. Soluble α-synuclein-antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia. Trudler D; Nazor KL; Eisele YS; Grabauskas T; Dolatabadi N; Parker J; Sultan A; Zhong Z; Goodwin MS; Levites Y; Golde TE; Kelly JW; Sierks MR; Schork NJ; Karin M; Ambasudhan R; Lipton SA Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33833060 [TBL] [Abstract][Full Text] [Related]
14. Echinacoside exerts neuroprotection via suppressing microglial α-synuclein/TLR2/NF-κB/NLRP3 axis in parkinsonian models. Yang XP; Huang JH; Ye FL; Yv QY; Chen S; Li WW; Zhu M Phytomedicine; 2024 Jan; 123():155230. PubMed ID: 38000105 [TBL] [Abstract][Full Text] [Related]
15. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations. Sahay S; Ghosh D; Singh PK; Maji SK Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727 [TBL] [Abstract][Full Text] [Related]
17. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins. Meredith SC Ann N Y Acad Sci; 2005 Dec; 1066():181-221. PubMed ID: 16533927 [TBL] [Abstract][Full Text] [Related]
18. Structural remodeling during amyloidogenesis of physiological Nα-acetylated α-synuclein. Gallea JI; Sarroukh R; Yunes-Quartino P; Ruysschaert JM; Raussens V; Celej MS Biochim Biophys Acta; 2016 May; 1864(5):501-10. PubMed ID: 26845568 [TBL] [Abstract][Full Text] [Related]
19. Lipoteichoic acid modulates inflammatory response in macrophages after phagocytosis of titanium particles through Toll-like receptor 2 cascade and inflammasomes. Naganuma Y; Takakubo Y; Hirayama T; Tamaki Y; Pajarinen J; Sasaki K; Goodman SB; Takagi M J Biomed Mater Res A; 2016 Feb; 104(2):435-44. PubMed ID: 26440284 [TBL] [Abstract][Full Text] [Related]
20. Biasing the native α-synuclein conformational ensemble towards compact states abolishes aggregation and neurotoxicity. Carija A; Pinheiro F; Pujols J; Brás IC; Lázaro DF; Santambrogio C; Grandori R; Outeiro TF; Navarro S; Ventura S Redox Biol; 2019 Apr; 22():101135. PubMed ID: 30769283 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]